Shares of CV Sciences CVSI were unhanged in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share fell 500.00% over the past year to ($0.04), which missed the estimate of ($0.03).
Revenue of $8,270,000 lower by 44.54% from the same period last year, which beat the estimate of $6,520,000.
Outlook
CV Sciences hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 08, 2020
Webcast URL: http://public.viavid.com/player/index.php?id=139612
Technicals
52-week high: $0.79
Company's 52-week low was at $0.35
Price action over last quarter: Up 37.63%
Company Overview
CV Sciences Inc is a pharmaceutical company. The group operates in two segments consumer products and specialty pharmaceutical. The consumer products segment develops, manufactures and markets products based on hemp-based Cannabidiol (CBD). Whereas the specialty pharmaceutical segment is developing drug candidates which use CBD as a primary active ingredient.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.